Viking Therapeutics (LTS:0VQA) Beta : -0.92 (As of Jun. 05, 2024)

Viking Therapeutics Beta Chart

Viking Therapeutics Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Beta		Get a 7-Day Free Trial					-	-	-	-	-0.16

Viking Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beta	Get a 7-Day Free Trial															-	-	-0.23	-0.16	-

Competitive Comparison of Viking Therapeutics's Beta

For the Biotechnology subindustry, Viking Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viking Therapeutics's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viking Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Viking Therapeutics's Beta falls into.

Viking Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Viking Therapeutics  (LTS:0VQA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Viking Therapeutics Beta Related Terms

Thank you for viewing the detailed overview of Viking Therapeutics's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.

Viking Therapeutics (LTS:0VQA) Business Description